Main exclusion criteria included BMI 20 kg/m2, type 1 diabetes, type 2 diabetes, if previously treated with insulin or with oral hypoglycemic or insulin-sensitizing agents, history of malignancy, and hypopituitarism
Common side effects such as nausea, vomiting, and gastrointestinal discomfort can deter patient adherence, especially during the early stages of treatment
Overall, this study hints at the possibility of considering anti-diabetic drugs with weight loss-inducing effects for potential repurposing opportunities in MS
Furthermore, AKT activates HIF-1 to transcriptionally upregulate glycolytic effectors including HKII, PDHK1, and LDHA [12]
However, the test subjects did experience the following minor side effects: Mild injection site reactions (pain, itching, swelling) Headaches Diarrhea, Hypertension Induration CJC-1295 administration has also been linked to mild, transitory side effects such as flushing, water retention, and insomnia [7]
Guarnieri, G